REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters

• Published in: bioRxiv
• Main Authors: Baum, Alina, Copin, Richard, Ajithdoss, Dharani, Zhou, Anbo, Lanza, Kathryn, Negron, Nicole, Ni, Min, Wei, Yi, Atwal, Gurinder S, Adelekan Oyejide, Goez-Gazi, Yenny, Dutton, John, Clemmons, Elizabeth, Staples, Hilary M, Bartley, Carmen, Klaffke, Benjamin, Alfson, Kendra, Gazi, Michal, Gonzales, Olga, Dick, Edward, Carrion, Ricardo, Pessaint, Laurent, Porto, Maciel, Cook, Anthony, Brown, Renita, Vaneesha Ali, Greenhouse, Jack, Taylor, Tammy, Andersen, Hanne, Lewis, Mark G, Stahl, Neil, Murphy, Andrew J, Yancopoulos, George D, Kyratsous, Christos A
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 03.08.2020
• Subjects: Antibodies; COVID-19; Epitopes; Patent applications; Severe acute respiratory syndrome coronavirus 2; Spike protein
• DOI: 10.1101/2020.08.02.233320

An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically. Our results provide evidence of the therapeutic potential of this antibody cocktail. Competing Interest Statement Regeneron authors own options and/or stock of the company. This work has been described in one or more pending provisional patent applications. N.S, A.J.M., G.D.Y. and C.A.K. are officers of Regeneron.